title: The leukocyte aggregation test: immunodiagnostic applications and immunotherapeutic implications for clinical renal transplantation.
abstract: The leukocyte aggregation test (LAT) detects the in vitro adhesion of sensitized, but not nonimmune, recipient leukocytes onto donor kidney cell monolayers. The test specifically detects cell-mediated homograft immunity up to 15 days prior to the appearance of clinical signs or alteration of chemical indexes. The presence of a positive reaction always signified incipient homograft rejection, which was usually controlled by intravenously administered, high-dose methylprednisolone sodium succinate (Solu-Medrol) therapy. There was no instance in which methyl-prednisolone treatment effectively reversed rejection in the presence of a negative leukocyte aggregation test. One common form of homograft rejection may be characterized by positive LAT results, a cellular infiltrate on the renal biopsy specimen, and sensitivity to methylprednisolone therapy.
mesh_terms: D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology; D002417:Cattle; D006084:Graft Rejection; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D007519:Isoantigens; D007668:Kidney / Q000276:immunology; D016030:Kidney Transplantation; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology*; D008775:Methylprednisolone / Q000494:pharmacology; D009392:Nephrectomy; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D000961:Antilymphocyte Serum; D007519:Isoantigens; D008775:Methylprednisolone